Fujisawa Pharmaceutical Company, Ltd.

Astellas Pharma Gmbh

Dai Nippon Printing Co., Ltd.

Yoshito Abe

Teruo Kyoto Oku

Hiroshi Kayakiri

Yuki Sawada

Hirokazu Tanaka

Shigeki Satoh

Tsuyoshi Mizutani

Takayuki Inoue

Noritsugu Yamasaki

Hitoshi Sawada

Takafumi Imoto

Takahiro Hiramura

Hitoshi Hamashima

Yoshio Kawai

Makoto Inoue

Masahiro Nishikawa

Hiroyuki Setoi

Hitoshi Yamazaki

Kazuhiko Ohne

Osamu Onomura

Hiroshi Marusawa

Naoki Ishibashi

Mitsuaki Okumura

Hideo Tsutsumi

Kozo Sawada

Hironori Harada

Sunao Imada

Masataka Morita

Kenichiro Imamura

Kazuyuki Hattori

Kazuya Fujita

Tatsuaki Morokata

Hiromichi Itani

Kentaro Sato

Tomohiro Oku

Noriko Oku

Noriko Oku, Legal Representative

Chikako Oku, Legal Representative

Tomohito Oku, Legal Representative

Chikaka Oku

To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1Pagonist activity. Since the compound of the invention has an S1Pagonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.

Hetero compound

The invention relates to compound of the formula (I) or its salt, in which R, R, Rand Rare as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-&#x3b1; mediated diseases. 

Pyrazolopyridine derivatives

In a computer generation of a dither mask for conversion of a continuous-tone image into a halftone image, a pixel array having a size in accordance with the dither mask is partitioned into blocks. Initial pixel values are determined such that the occurrences of pixel values will be substantially uniform in the blocks. A pair of exchange target pixels are selected at random from the pixels in one of the blocks and function values of a predetermined evaluation function that indicates a characteristic of the pixel value configuration of the pixels in this block are computed for the two cases where pixel values are exchanged among the exchange target pixels and where not exchanged. These function values are compared to judge whether exchange should be performed.

Dither mask creating method and creating device

The invention relates to compound of the formula (I) or its salt, in which R, R, Rand Rare as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-&#x3b1; mediated diseases 

Pyrrolopyridazine derivatives

Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.

Imidazole compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R&#x2014;SONHCO&#x2014;A&#x2014;X&#x2014;R&#x2003;&#x2003;(I)wherein Ris alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and Ris optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Sulfonamide compounds and pharmaceutical use thereof

The present invention relates to a sulfonamide compound of the formula (I):wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.

Sulfonamide compounds and uses thereof as medicines

Sulfonamide compounds and medicinal use thereof

Heterocyclic compounds as bradykinin antagonists

Novel aromatic ring derivatives represented by formula (I) or their pharmaceutical acceptable salts are provided.

Aromatic ring derivatives

This invention relates to a heterocyclic compound of the formula

Benzimidazole compounds as bradykinin antagonists

The invention relates to a pharmaceutical composition for ophthalmic administration comprising a compound of the formula:

Bradykinin antagonist quinolines

Growing community of inventors

Ibaraki, Japan

Yoshito Abe